TSHA Taysha Gene Therapies Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TSHA

Price (delayed)

$4.91

Market cap

$1.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$1.2B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 22

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate its treatments from bench to ...

Highlights
The company's equity has surged by 83% QoQ and by 56% YoY
Taysha Gene Therapies's quick ratio has increased by 41% YoY and by 26% QoQ
Taysha Gene Therapies's net income has shrunk by 61% YoY and by 15% QoQ
Taysha Gene Therapies's revenue has decreased by 32% YoY and by 27% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tayshagtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TSHA

TSHA stock price

How has the Taysha Gene Therapies stock price performed over time
Intraday
-4.84%
1 week
-3.16%
1 month
-19.38%
1 year
68.15%
YTD
-10.73%
QTD
-27.9%

Financial performance

How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$5.49M
Gross profit
$5.49M
Operating income
-$153.16M
Net income
-$149.63M
Gross margin
100%
Net margin
-2,728%
TSHA's operating margin has shrunk by 141% YoY and by 57% QoQ
The net margin has plunged by 138% YoY and by 57% from the previous quarter
The operating income has dropped by 63% year-on-year and by 16% since the previous quarter
Taysha Gene Therapies's net income has shrunk by 61% YoY and by 15% QoQ

Price vs fundamentals

How does TSHA's price correlate with its fundamentals

Growth

What is Taysha Gene Therapies's growth rate over time

Valuation

What is Taysha Gene Therapies stock price valuation
TSHA P/E details
P/E
N/A
P/B
3.64
P/S
330.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
218.75
Taysha Gene Therapies's EPS has decreased by 24% YoY and by 11% QoQ
The company's equity has surged by 83% QoQ and by 56% YoY
TSHA's price to book (P/B) is 72% lower than its 5-year quarterly average of 13.6 and 28% lower than its last 4 quarters average of 5.3
TSHA's price to sales (P/S) is 33% more than its last 4 quarters average of 260.1
Taysha Gene Therapies's revenue has decreased by 32% YoY and by 27% QoQ

Efficiency

How efficient is Taysha Gene Therapies business performance
Taysha Gene Therapies's return on sales has shrunk by 138% YoY and by 57% QoQ
The return on invested capital has declined by 49% year-on-year and by 18% since the previous quarter
TSHA's ROE is up by 30% year-on-year
Taysha Gene Therapies's return on assets has increased by 9% YoY but it has decreased by 4% QoQ

Dividends

What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TSHA.

Financial health

How did Taysha Gene Therapies financials performed over time
The company's total assets has surged by 57% QoQ and by 41% YoY
The current ratio is up by 42% year-on-year and by 26% since the previous quarter
The debt is 86% less than the equity
The company's equity has surged by 83% QoQ and by 56% YoY
Taysha Gene Therapies's debt to equity has shrunk by 55% QoQ and by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.